Connect to MCP

Claude DesktopClaude Code (CLI)ChatGPTCursorVS Code

Apollomics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Apollomics.

Start Free TrialSee companies similar to Apollomics

Apollomics Overview

About Apollomics

Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

Founded

2016

HQ

United States

Employees

13

Financials (FY)

Revenue: $9M
EBITDA: ($11M)

EV

$36M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Apollomics Financials

Apollomics reported last fiscal year revenue of $9M and negative EBITDA of ($11M).

In the same fiscal year, Apollomics generated ($11M) in EBITDA losses and had net loss of ($11M).

Apollomics P&L

In the most recent fiscal year, Apollomics reported revenue of $9M and EBITDA of ($11M).

Apollomics is unprofitable as of last fiscal year, with EBITDA margin of (125%) and net margin of (129%).

See analyst estimates for Apollomics
Last FY202320242025202620272028
Revenue$9M--$9M
EBITDA($11M)($172M)($53M)($11M)
EBITDA Margin(125%)--(125%)
EBIT Margin(108%)--(108%)
Net Profit($11M)($173M)($54M)($11M)
Net Margin(129%)--(129%)

Financial data powered by Morningstar, Inc.

Apollomics Stock Performance

Apollomics has current market cap of $38M, and enterprise value of $36M.

Apollomics' stock price is $17.37.

Apollomics has an EPS (earnings per share) of $-4.98.

See more trading valuation data for Apollomics
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$36M$38M1.8%---$-4.98

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Apollomics Valuation Multiples

Apollomics trades at 4.2x EV/Revenue multiple, and (3.3x) EV/EBITDA.

See NTM and 2027E valuation multiples for Apollomics

Apollomics Financial Valuation Multiples

As of August 14, 2026, Apollomics has market cap of $38M and EV of $36M.

Apollomics has a P/E ratio of (3.5x).

Last FY202320242025202620272028
EV/Revenue4.2x--4.2x
EV/EBITDA(3.3x)(0.2x)(0.7x)(3.3x)
EV/EBIT(3.9x)(0.7x)(0.8x)(3.9x)
P/E(3.5x)(0.2x)(0.7x)(3.5x)
EV/FCF(3.4x)(0.8x)(1.2x)(3.4x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Apollomics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Apollomics Margins & Growth Rates

In the most recent fiscal year, Apollomics reported EBITDA margin of (125%) and net margin of (129%).

See estimated margins and future growth rates for Apollomics

Apollomics Margins

Last FY2025202720282029
EBITDA Margin(125%)(125%)
EBIT Margin(108%)(108%)
Net Margin(129%)(129%)
FCF Margin(122%)(122%)

Apollomics Growth Rates

23/2424/2526/2727/2828/29
EBITDA Growth(69%)(80%)
EBIT Growth(23%)(78%)
Net Profit Growth(69%)(80%)
FCF Growth(33%)(64%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Apollomics Operational KPIs

Apollomics' revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $1.4M for the same period.

Access forward-looking KPIs for Apollomics
Last FY2025202620272028
Revenue per Employee$0.7M-
Opex per Employee$1.4M-
G&A Expenses to Revenue146%146%
R&D Expenses to Revenue65%65%
Opex to Revenue208%208%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Digital TherapeuticsHorizontal MarketplacesInvestment BankingERP SoftwareDeveloper ToolsConsumer SaaSStreamingVertical SaaSNetworking HardwareFinancial Data & InformationEnergy StorageRoad InfrastructureSemiconductors
Explore Valuation Multiples by Industry

Apollomics Competitors

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E

This data is available for Pro users. Sign up to see all Apollomics competitors and their valuation data.

Start Free Trial

Apollomics VC Funding History

Before going public, Apollomics raised $239M in total equity funding, across 4 rounds.

Last private valuation of Apollomics was $899M, after raising $124M in November 2020 from Ping An Capital and WR Hambrecht.

Apollomics Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Nov-20Series CPing An Capital; WR Hambrecht$124M$899MApollomics is a US biopharmaceutical company initially incubated by OrbiMed Asia. In November 2020, the company raised $124.2 million in a Series C funding round led by Ping An Capital (Ping An Insurance Group's investment vehicle), with participation from CMB International and other undisclosed investors. The round valued the company at $899 million post-money. The company has raised a total of $239.11 million across multiple funding rounds since its inception.
Jan-19Series BSouth China Venture Capital; K2VC; Guangzhou Yue Min Investment; CMB International Capital Corporation; Junson Capital; OrbiMed; Pan-Lin Capital$100M-Apollomics, Inc. (previously CBT Pharmaceuticals, Inc.), an innovative biopharmaceutical company focused on the discovery and development of oncology combination therapies, raised $100 million in a Series B financing announced on January 7, 2019. The round was led by CMB International Capital Corporation (CMBI), a subsidiary of China Merchants Bank, with participation from existing Series A investor OrbiMed Asia and several new investors including Guangzhou Yue Min Investment, Junson Capital, K2VC, Pan-Lin Capital, and South China Venture Capital. The funding supports expansion of clinical development programs globally, leveraging the company's presence in the United States, China, and Australia. Apollomics aims to become a global leader in novel cancer medicines through combination regimens to achieve clinically meaningful, durable responses. CEO Guo-Liang Yu, also an OrbiMed Venture Partner, highlighted the company's vision and positioning for growth with this capital. CMBI's Dr. Kexiang Zhou emphasized the appeal of Apollomics' cross-border presence, diverse pipeline, proven track record, and seasoned management team.
Aug-16Series AOrbiMed$10M-CBT Pharmaceuticals (later renamed Apollomics) closed a $9.75 million Series A financing on August 29, 2016, led by OrbiMed Asia, with total capital raised of $14.75 million including warrants. The financing was designed to advance two of the company's four development programs into human clinical trials. The company was a life sciences firm focused on developing innovative oncology therapeutics, advancing a pipeline of four development-stage assets including CBT-101, an oral c-Met inhibitor targeting the epithelial to mesenchymal transition (EMT) pathway in cancers, and CBT-501, a novel humanized monoclonal antibody targeting the Programmable Death-1 (PD-1) membrane receptor of immune cells.
Jan-16Seed-$5M-Apollomics, formerly CBT Pharmaceuticals, raised $9.75 million in a Series A financing led by OrbiMed in 2016, bringing total capital to $14.75 million including $5 million seed funding from parent company Crown Bioscience International. The funds advanced targeted medicine and immune-oncology programs, including CBT-101 (c-MET inhibitor) and CBT-501 (anti-PD-1 antibody), into clinical trials. The company focused on oncology assets addressing epithelial to mesenchymal transition and immune checkpoint pathways.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Apollomics

When was Apollomics founded?Apollomics was founded in 2016.
Where is Apollomics headquartered?Apollomics is headquartered in United States.
How many employees does Apollomics have?As of today, Apollomics has over 13 employees.
Is Apollomics publicly listed?Yes, Apollomics is a public company listed on Nasdaq.
What is the stock symbol of Apollomics?Apollomics trades under APLM ticker.
When did Apollomics go public?Apollomics went public in 2023.
Who are competitors of Apollomics?Apollomics main competitors include
What is the current market cap of Apollomics?Apollomics' current market cap is $38M.
What is the current revenue of Apollomics?Apollomics' last fiscal year revenue is $9M.
What is the current EV/Revenue multiple of Apollomics?Current revenue multiple of Apollomics is 4.2x.
Is Apollomics profitable?No, Apollomics is not profitable.
How many companies Apollomics has acquired to date?Apollomics hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Apollomics has invested to date?Apollomics hasn't invested in any companies yet (or none have been disclosed publicly).

Lists including Apollomics

Largest Companies in the US

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial